Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040266714
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 27, 2004
    Publication date: December 30, 2004
    Inventors: Susan Freier, Kenneth W. Dobie, Robert McKay
  • Publication number: 20040253723
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: February 26, 2004
    Publication date: December 16, 2004
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: George Tachas, Kenneth W. Dobie, Ravi Jain, Christopher Belyea, Mark A. Heffernan
  • Patent number: 6828151
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hematopoietic cell protein tyrosine kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hematopoietic cell protein tyrosine kinase. Methods of using these compounds for modulation of hematopoietic cell protein tyrosine kinase expression and for treatment of diseases associated with expression of hematopoietic cell protein tyrosine kinase are provided.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: December 7, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Alexander H. Borchers, Kenneth W. Dobie
  • Publication number: 20040224912
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PAI-1 mRNA-binding protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding PAI-1 mRNA-binding protein. Methods of using these compounds for modulation of PAI-1 mRNA-binding protein expression and for diagnosis and treatment of disease associated with expression of PAI-1 mRNA-binding protein are provided.
    Type: Application
    Filed: May 7, 2003
    Publication date: November 11, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Donna T. Ward
  • Publication number: 20040220393
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1&agr; and/or HIF2&agr;. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1&agr; and HIF2&agr;. Methods of using these compounds for modulation of HIF1&agr; and/or HIF2&agr; expression and for diagnosis and treatment of disease associated with expression of HIF1&agr; and/or HIF2&agr; are provided.
    Type: Application
    Filed: November 21, 2003
    Publication date: November 4, 2004
    Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier
  • Publication number: 20040215006
    Abstract: Compounds, compositions and methods are provided for modulating the expression of tyrosinase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding tyrosinase. Methods of using these compounds for modulation of tyrosinase expression and for diagnosis and treatment of disease associated with expression of tyrosinase are provided.
    Type: Application
    Filed: April 25, 2003
    Publication date: October 28, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas Condon, Susan M. Freier, Kenneth W. Dobie
  • Publication number: 20040208856
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Application
    Filed: April 16, 2003
    Publication date: October 21, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Publication number: 20040180847
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Application
    Filed: November 17, 2003
    Publication date: September 16, 2004
    Inventors: Kenneth W. Dobie, Erich Koller
  • Publication number: 20040137441
    Abstract: Compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding thyroid hormone receptor interactor 3. Methods of using these compounds for modulation of thyroid hormone receptor interactor 3 expression and for diagnosis and treatment of disease associated with expression of thyroid hormone receptor interactor 3 are provided.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 15, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie, Ravi Jain
  • Publication number: 20040132681
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of beta-site APP-cleaving enzyme 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding beta-site APP-cleaving enzyme 2. Methods of using these compounds for modulation of beta-site APP-cleaving enzyme 2 expression and for treatment of diseases associated with expression of beta-site APP-cleaving enzyme 2 are provided.
    Type: Application
    Filed: September 16, 2003
    Publication date: July 8, 2004
    Inventor: Kenneth W. Dobie
  • Publication number: 20040127451
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 6. Methods of using these compounds for modulation of dual specific phosphatase 6 expression and for treatment of diseases associated with expression of dual specific phosphatase 6 are provided.
    Type: Application
    Filed: February 9, 2004
    Publication date: July 1, 2004
    Inventors: Brett P. Monia, Lex M. Cowsert, Kenneth W. Dobie
  • Publication number: 20040126761
    Abstract: Compounds, compositions and methods are provided for modulating the expression of alpha-methylacyl-CoA racemase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding alpha-methylacyl-CoA racemase. Methods of using these compounds for modulation of alpha-methylacyl-CoA racemase expression and for diagnosis and treatment of disease associated with expression of alpha-methylacyl-CoA racemase are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: July 1, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Ravi Jain
  • Publication number: 20040121328
    Abstract: Compounds, compositions and methods are provided for modulating the expression of phosphodiesterase 8A. The compositions comprise oligonucleotides, targeted to nucleic acid encoding phosphodiesterase 8A. Methods of using these compounds for modulation of phosphodiesterase 8A expression and for diagnosis and treatment of disease associated with expression of phosphodiesterase 8A are provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: June 24, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Publication number: 20040115653
    Abstract: Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.
    Type: Application
    Filed: December 12, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Publication number: 20040115638
    Abstract: Compounds, compositions and methods are provided for modulating the expression of tumor susceptibility gene 101. The compositions comprise oligonucleotides, targeted to nucleic acid encoding tumor susceptibility gene 101. Methods of using these compounds for modulation of tumor susceptibility gene 101 expression and for diagnosis and treatment of disease associated with expression of tumor susceptibility gene 101 are provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Publication number: 20040115633
    Abstract: Compounds, compositions and methods are provided for modulating the expression of mitochondrial ribosome protein S16. The compositions comprise oligonucleotides, targeted to nucleic acid encoding mitochondrial ribosome protein S16. Methods of using these compounds for modulation of mitochondrial ribosome protein S16 expression and for diagnosis and treatment of disease associated with expression of mitochondrial ribosome protein S16 are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Tamara Balac Sipes
  • Publication number: 20040115641
    Abstract: Compounds, compositions and methods are provided for modulating the expression of ROCK 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ROCK 1. Methods of using these compounds for modulation of ROCK 1 expression and for diagnosis and treatment of disease associated with expression of ROCK 1 are provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Lex M. Cowsert, Kenneth W. Dobie
  • Publication number: 20040115637
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PPAR-alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding PPAR-alpha. Methods of using these compounds for modulation of PPAR-alpha expression and for diagnosis and treatment of disease associated with expression of PPAR-alpha are provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Kenneth W. Dobie
  • Publication number: 20040115650
    Abstract: Compounds, compositions and methods are provided for modulating the expression of MAD1-like 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding MAD1-like 1. Methods of using these compounds for modulation of MAD1-like 1 expression and for diagnosis and treatment of disease associated with expression of MAD1-like 1 are provided.
    Type: Application
    Filed: December 12, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Ravi Jain
  • Publication number: 20040115652
    Abstract: Compounds, compositions and methods are provided for modulating the expression of TEK. The compositions comprise oligonucleotides, targeted to nucleic acid encoding TEK. Methods of using these compounds for modulation of TEK expression and for diagnosis and treatment of disease associated with expression of TEK are provided.
    Type: Application
    Filed: December 12, 2002
    Publication date: June 17, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Lex M. Cowsert, Kenneth W. Dobie